{Reference Type}: Case Reports
{Title}: A case of pembrolizumab and lenvatinib as an alterntive therapy for leiomyosarcoma.
{Author}: Mehta N;Lee SS;Salame G;
{Journal}: Gynecol Oncol Rep
{Volume}: 45
{Issue}: 0
{Year}: Feb 2023
暂无{DOI}: 10.1016/j.gore.2023.101145
{Abstract}: •Research surrounding treatment of leiomyosarcoma (LMS) treatment remains sparse.•Pembrolizumab/lenvatinib has been reported as a therapy for endometrial cancer, though not yet as therapy for LMS.•This report demonstrates disease regression after use of pembrolizumab and lenvatinib in a patient with recurrent LMS.